Organon & Co. (NYSE:OGN – Free Report) had its target price lifted by The Goldman Sachs Group from $18.00 to $20.00 in a research report released on Friday morning, Benzinga reports. They currently have a neutral rating on the stock.
Separately, Piper Sandler lifted their price target on shares of Organon & Co. from $22.00 to $24.00 and gave the stock an overweight rating in a report on Monday, April 29th.
Check Out Our Latest Analysis on Organon & Co.
Organon & Co. Price Performance
Organon & Co. (NYSE:OGN – Get Free Report) last posted its quarterly earnings data on Thursday, February 15th. The company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.14. The business had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.55 billion. Organon & Co. had a negative return on equity of 259.73% and a net margin of 16.50%. Equities research analysts predict that Organon & Co. will post 4.1 earnings per share for the current year.
Organon & Co. Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 13th. Shareholders of record on Monday, May 13th will be issued a $0.28 dividend. This represents a $1.12 annualized dividend and a yield of 5.71%. The ex-dividend date of this dividend is Friday, May 10th. Organon & Co.’s dividend payout ratio (DPR) is 27.38%.
Insider Activity
In related news, insider Kirke Weaver bought 2,720 shares of the stock in a transaction that occurred on Thursday, February 22nd. The stock was purchased at an average cost of $18.36 per share, for a total transaction of $49,939.20. Following the completion of the acquisition, the insider now owns 15,181 shares in the company, valued at $278,723.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.17% of the company’s stock.
Hedge Funds Weigh In On Organon & Co.
A number of hedge funds have recently made changes to their positions in the stock. Exchange Traded Concepts LLC purchased a new stake in Organon & Co. during the third quarter valued at about $165,000. Cambridge Investment Research Advisors Inc. increased its position in Organon & Co. by 8.2% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 24,159 shares of the company’s stock worth $419,000 after purchasing an additional 1,838 shares in the last quarter. Xponance Inc. raised its holdings in Organon & Co. by 4.4% in the third quarter. Xponance Inc. now owns 42,535 shares of the company’s stock valued at $738,000 after buying an additional 1,798 shares during the period. Raymond James & Associates lifted its position in Organon & Co. by 0.7% during the third quarter. Raymond James & Associates now owns 345,810 shares of the company’s stock valued at $6,003,000 after buying an additional 2,354 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. grew its stake in Organon & Co. by 13.7% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 82,800 shares of the company’s stock worth $1,437,000 after buying an additional 9,956 shares during the period. Institutional investors and hedge funds own 77.43% of the company’s stock.
About Organon & Co.
Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.
Recommended Stories
- Five stocks we like better than Organon & Co.
- What Are Dividends? Buy the Best Dividend Stocks
- MarketBeat Week in Review – 4/29 – 5/3
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- The Significance of Brokerage Rankings in Stock Selection
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.